Background. Few studies have evaluated survival rates among women who have chronic hepatitis B virus infection. We investigated the overall and disease-specific mortality rates in a nationwide cohort of women after they were screened for hepatitis B surface antigen (HBsAg) during pregnancy.
Several extrahepatic manifestations of HBV infection have been reported [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Immune-complex deposition resulting in polyarteritis nodosa among persons with HBV infection has been reported primarily from Western countries [3, 4] . Several investigators have examined the possible role of chronic HBV infection in the pathogenesis of carotid atherosclerosis, perhaps due to HBV activation of inflammatory pathways [5] [6] [7] . Findings in other studies have suggested that HBV may play a role in the etiology of non-Hodgkin lymphoma (NHL) [8] [9] [10] [11] [12] [13] . In addition to these clinical observations, virological studies have detected HBV DNA in tissues other than the liver, such as the kidney, pancreas, and peripheral mononuclear cells [14, 15] . Chronic active HBV infection could promote the pathogenesis of some non-liver-related diseases because of chronic inflammation or persistent antigenemia.
In order to examine the association of chronic HBV infection with all-cause and disease-specific mortality, we evaluated mortality rates in a cohort of women in Taiwan who were screened for hepatitis B surface an-tigen (HBsAg) during their pregnancy as part of a national program to prevent HBV transmission to newborn infants.
METHODS

Data sources and study population.
A retrospective population-based cohort study was conducted by linking individual records from 2 nationwide databases, the National Hepatitis B Vaccination Registry and the National Death Certification Registry, by use of the resident-registry number, which is a unique identifier that is assigned to each resident of Taiwan.
The National Hepatitis B Vaccination Registry has been described elsewhere [16] . Briefly, it was established in 1983 and records information on pregnant women's HBV status. Enzyme immunoassay (EIA), radioimmunoassay (RIA), and reversed passive hemagglutination assay (RPHA) were used to test for HBV antigens. For the first several years after the initiation of the national vaccination program, RPHA was used as an alternate testing method if the standard EIA or RIA was unavailable at some laboratories. Prior experience with the use of RPHA as a substitute for EIA or RIA was satisfactory [17] . The National Death Certification Registry contains information about the date and causes of death of all Taiwan residents. The cause of death was coded according to the International Classification of Diseases, Ninth Revision (ICD-9).
Because the National Death Certification Registry was available from the year 1985, we included in our analysis all women in the National Hepatitis B Vaccination Registry whose HBsAg status was determined between 1 January 1986 and 31 March 2000. The sample for analysis in this study consisted of 2,087,994 women, after excluding those women whose age was not recorded at the time of their test ( ). In total, n p 1075 1,529,191 (73%) of the test results were from either EIA or RIA. No statistically significant differences in geographic distributions were observed between testing methods using EIA/ RIA or RPHA.
Ascertainment of HBV carrier and vital status. We determined the HBsAg status of each woman in this study from her first serological test result that was reported by prenatal care providers to the National Hepatitis B Vaccination Registry. Vital status was ascertained by computerized linkage of the National Hepatitis B Vaccination Registry data with the National Death Certification Registry. Persons not linked to a death record were considered to be alive through the end of follow-up and were censored on 31 December 2003.
Statistical analyses. Entry into the cohort was defined as the date of first prenatal testing for HBV. The duration of follow-up for each subject was calculated from enrollment to the date of death, or the date of last available information from the National Death Certification Registry on 31 December 2003. Censored individuals were those still living at the end of followup. For analyses of cause-specific mortality, persons who died of other causes were also censored at the date of death. The number of events and the mortality rate by specific cause of death (ie, event number divided by person-years of follow-up) were calculated. Associations between HBsAg status at enrollment and all-cause or disease-specific mortality, adjusted for age at enrollment, were estimated using the Cox proportional hazards model to calculate hazard ratios (HRs) and their corresponding 95% confidence interval (CI). Follow-up duration was used as the time metric in the analysis. The assumption of proportionality for the Cox analysis was tested by examining the interaction between HBsAg status and follow-up time, and no violation of this assumption was observed. The mortality curves by follow-up years were derived with the Kaplan-Meier method. The log-rank test was used to compare curves. Statistical significance level was defined as a P-value of !.05 by 2-tailed tests. We also calculated the population-attributable risk, which was expressed as the percentage change of mortality rate from the rate among the overall HBsAg-positive and HBsAgnegative population to that among the HBsAg-negative population for all-cause and liver-specific mortality.
The causes of death of greatest interest were liver-specific causes: malignant neoplasm of the liver and intrahepatic bile ducts (ICD-9 code 155), viral hepatitis (ICD-9 code 070), acute and subacute necrosis of the liver (ICD-9 code 570), chronic liver disease and cirrhosis (ICD-9 code 571), liver abscess and sequelae of chronic liver disease (ICD-9 code 572), and other disorders of the liver (ICD-9 code 573). The other non-liverrelated causes of death were divided into 2 groups: cancer deaths and noncancer deaths. In addition, the leading causes of death from cancer among women in Taiwan during the period from 1991 to 2004 [18] were evaluated as well, comparing the mortality rate among HBsAg-positive women with that among HBsAg-negative women in this cohort.
SAS statistical software (version 9.2; SAS Institute) was used for all analyses. The graphs of Kaplan-Meier estimates were plotted using STATA statistical software (version 8.2; STATA Corp). All personal identifiers were removed before the linked data were transferred for data analysis. Because there were no identifiers or links to identifiers in this data set, the study was exempt from human subject review by the Committee on Human Research at the Johns Hopkins Bloomberg School of Public Health, which included a waiver of the requirement for informed consent of participating women.
RESULTS
A total of 2,087,994 women were included in this analysis. Among them, 313,749 (15.03%) women were HBsAg positive at enrollment. The prevalence of HBsAg was consistent with prior estimates in Taiwan [19, 20] 26 years). The detailed age distribution and the prevalence of HBsAg for each age group are shown in Table 1 .
All-cause mortality. After a mean of years 11.43 ‫ע‬ 4.11 (‫ע‬SD; median, 11.68 years) of follow-up, there were 14,524 deaths during 23,858,711 person-years. The number of deaths, mortality rate, age-adjusted HR, and population-attributable risk are shown in Table 2 . The all-cause mortality rate was 60.88 per 100,000 person-years; it was 72.02 and 58.90 per 100,000 person-years in HBsAg-positive and HBsAg-negative women, respectively. HBsAg-positive women had a 24% increase in all-cause mortality, compared with HBsAg-negative women (age-adjusted HR, 1.24; 95% CI, 1.19-1.30). Figure 1 shows the cumulative mortality rate of all-cause mortality by HBsAg status at enrollment. After 4-5 years of follow-up, women who were HBsAg positive had persistently higher allcause cumulative mortality. The overall mortality for HBsAgpositive women was statistically significantly higher than that of HBsAg-negative women ( ). P ! .001
Liver-specific mortality. There were 740 liver-specific deaths overall, 356 in the cancer group and 384 in the noncancer group ( Non-liver-related mortality. The mortality rates were 57.77 per 100,000 person-years for all non-liver-related causes, 19.62 for cancers, and 38.16 for noncancer diseases. The HBsAg-positive group had significantly higher mortality rate for all non-liver-related causes (age-adjusted HR, 1.09; 95% CI, 1.04-1.14) and cancers (HR, 1.20; 95% CI, 1.11-1.30), compared with that in the HBsAg-negative group. The noncancer group had a slight but insignificant increased mortality risk of 1.03 (95% CI, 0.97-1.09). In contrast, mortality related to diseases of the skin and subcutaneous tissue and of the musculoskeletal system and connective tissue occurred less frequently among HBsAg-positive women (Table 3) . Table 4 lists the HRs for the leading causes of death from cancer among HBsAg-positive women compared with those among HBsAg-negative women. In addition to liver cancer, women with HBV infection experienced a significantly increased risk of malignant neoplasm of the cervix uteri (ICD-9 code 180; age-adjusted HR, 1.35; 95% CI, 1.03-1.77), malignant neoplasm of gallbladder and extrahepatic bile ducts (ICD-9 code 156; HR, 2.02; 95% CI, 1.15-3.56), and non-Hodgkin lymphoma (ICD-9 code 200, 202; HR, 2.43; 95% CI, 1.75-3.38).
DISCUSSION
We found an increased all-cause mortality associated with HBsAg seropositivity among a nationwide, population-based cohort study involving more than 2 million parous women in Taiwan, with a mean follow-up period of more than 11 years. As expected, the risk of mortality from liver cancer and other liver-specific causes was markedly increased among HBsAg carriers. However, we also found significantly increased mortality among HBsAg-infected women due to several non-liver-related causes, raising questions concerning whether HBV infection could play a role in their etiology or whether confounding exists between HBV infection and other etiologic factors.
Several other studies from various populations have revealed elevated mortality associated with chronic HBV infection, as measured by HBsAg seropositivity [21] [22] [23] [24] [25] . The design of this study more closely resembled a study reported from China, in which a community cohort was screened for HBsAg, and the population was followed up prospectively for overall and causespecific mortality [21, 22] . Both this study and the study in China had similar length of follow-up (ie, ∼10 years) and found an increase in all-cause mortality associated with baseline HBsAg seropositivity among women. However, the adjusted risk estimate in the Chinese study was more than double (ageadjusted HR, 3.0) [21] that in our population (age-adjusted HR, 1.2). This difference might be due to the fact that our population was significantly younger than subjects in the Chinese study (ie, only 26 years of median age at enrollment, whereas 75% of the women in the Chinese study were 35-64 years old). Our population had an age-adjusted HR of 6.6 for liver-specific death compared with an age-adjusted HR of 20.9 in the study from China, which suggests that much of the overall mortality difference in these 2 studies was related to the risk for liver disease. This study involving a cohort of young women found an important impact of chronic HBV carriage on subsequent mortality, which was similar to women observed in other older populations. Another cohort study in Taiwan with 12 years of follow-up also found a significantly higher allcause mortality (adjusted HR, 1.7) in HBsAg-positive women compared with that in HBsAg-negative women at recruitment [26] . In the study of a middle-aged population, liver-specific causes accounted for 179 (42%) of 425 deaths among HBsAgpositive participants and only 71 (5%) of 1389 deaths among participants without evidence of chronic HBV infection. The proportion of liver-specific deaths in this study was smaller (15% for HBsAg-positive women and 3% for HBsAg-negative women). Because the mean age of diagnosis of HCC among women in Taiwan is 55 years [27] , our study population was still younger than the age associated with the highest risk of HCC. Because HCC has been documented to be the second leading cause of death from cancer among women in Taiwan since the early 1980s [28, 29] , we anticipate that the age-adjusted HR for HCC among HBV-infected women in this study will increase with additional follow-up.
Compared with the risk estimates for liver-specific causes of death, our age-adjusted HRs for non-liver-related causes of death were much closer to those of an older Chinese cohort that was recruited by means of community screening in Haimen City, China [21] (HR, 1.1 vs 1.4) . The risk for non-liver-related mortality in women was elevated in our cohort and the cohort from China but not in studies reported from other countries where the HBsAg prevalence was lower [23, 30] . The reason for this difference is unclear. However, the increased risk of deaths from non-liver-related causes in this study may be bi- ased to some extent because the death certificates recorded only the primary cause of death. Other secondary causes of death were not available in our database. We could not exclude the possibility that the increased risk of death from non-liver-related causes was confounded by analyzing only the primary cause of death in persons who had multiple causes of death. However, there is no reason to believe that the primary cause of death among HBsAg-positive individuals would frequently be recorded as non-liver-related diseases. Therefore, although there might be the potential for nondifferential misclassification of the cause of death in this study, it may result in only an underestimate of the true association. The association between HBV infection and NHL has been examined in several case-control studies. Most of these studies have found a higher prevalence of HBV infection among NHL patients than among patients with other non-liver-related cancers [8] [9] [10] [11] [12] . Two prospective studies have found chronic HBV infection to be significantly associated with NHL [13, 30] . Because NHL affects males more frequently and is more common in non-Hispanic whites than in other racial or ethnic groups [31] , prospective studies of the disease are more commonly conducted in Western countries. To our knowledge, our study is the first cohort study to document the association between chronic HBV infection and increased NHL mortality in a female Asian population. Recently, the International Agency for Research on Cancer has documented NHL as having a positive association with hepatitis C virus and possibly with HBV [32] . Through chronic immune stimulation, persistent hepatitis C infection is associated with essential mixed cryoglobulinemia, a low-grade lymphoproliferative disorder that can progress to NHL [33] . HBV infections are also lymphotropic, and the virus can be detected in mononuclear cells [34] . The significantly positive association of chronic HBV infection with NHL mortality in this study provides important epidemiological evidence to support an etiological role for HBV infection in NHL.
Women who were HBsAg positive in our study also experienced significantly increased rates of mortality from carcinoma of the gallbladder and extrahepatic bile ducts. This increased risk has not been found in most other studies of HBV-infected women. However, our population of HBsAg-positive women is considerably larger than that of previously reported studies. One population-based case-control study conducted in China found a 2.4-fold increased prevalence of HBsAg among patients with extrahepatic bile duct cancer compared with healthy control participants and subjects with biliary tract stones [35] . The mechanism by which HBV infection may lead to the development of extrahepatic bile duct cancer is unknown; however, a clinical investigation has detected HBV DNA in tissue specimens from extrahepatic bile duct cancers [36] .
Inconsistent with the findings of other studies [5] [6] [7] 37 , 38], we found an association of chronic HBV infection with cervical cancer and skin or musculoskeletal diseases, but not with pancreatic cancer and cardiovascular disease. The numbers of deaths from pancreatic cancer and skin or musculoskeletal diseases were relatively small in this study. Data were not available in this study to adjust for the effect of known risk factors for these diseases, such as family history, socioeconomic class, cigarette smoking, dietary intake, and coinfection with other agents. The observed associations may be confounded by some of these unmeasured variables. Additional studies are needed to evaluate these associations and explore underlying mechanisms in other populations with varying risks of chronic HBV infection. As previously reported [16] , other limitations of this administrative data set also included the concern of internal validity and the generalizability of the findings.
Despite these limitations, our study involving a large cohort of women with a high prevalence of chronic HBV infectionwith excellent follow-up and careful documentation of mortality-yielded important new information on the effect of HBV on mortality rates among women. Specifically, our study evaluated mortality in the Taiwanese population during a period when treatment of asymptomatic carriers of HBV was extremely uncommon; therefore, HBV therapy is unlikely to have influenced our findings. After an average of more than 11 years follow-up of the cohort, we found significantly increased mortality due to both liver and non-liver-related causes. Overall, mortality was increased by ∼25% among women with chronic HBV infection. In addition to markedly increased risk for hepatocellular carcinoma and chronic liver disease, we also observed substantially increased mortality risk for non-liverrelated cancers, namely, NHL and extrahepatic biliary cancers. Our data strongly support the public health importance of programs to vaccinate against and successfully treat chronic HBV infections in women; benefits are likely to be observed not only in prevention of liver disease progression but also in ameliorating morbidity and mortality from other causes.
